Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chromomycosis is a chronic cutaneous and subcutaneous fungal infection, found mainly in subtropical and tropical areas (in soil and plant debris and transmitted by traumatic inoculation), and characterized clinically by slow growing, verrucous nodules, squamous plaques, or chronic limited lesions which are most commonly found on the lower limbs and which are characterized histologically by the presence of muriform cells. It is caused by dematiaceous fungi, with the main etiological agents being Fonsecaea pedrosoi, Phialophora verrucosa and Cladophialophora carrionii. Rarely, it can be caused by Rhinocladiella aquaspersa.
Biomarker and diagnostic research for chromomycosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for chromomycosis.
200 publications have been identified in PubMed for chromomycosis. Kisho has analyzed 149 by research type. Research spans Case Report / Case Series (32%), Review / Meta-Analysis (26%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 47 | 32% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:42 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
39 |
26% |
Laboratory research | 22 | 15% |
Disease patterns and progression | 22 | 15% |
Other research | 8 | 5% |
Testing and diagnosis research | 6 | 4% |
Clinical study results | 3 | 2% |
New treatment approaches | 2 | 1% |
Kelly M (2026). [PMID: 41892077](https://pubmed.ncbi.nlm.nih.gov/41892077/). *Dermatopathology (Basel)*. [Case Report / Case Series]
Anwar S (2026). [PMID: 42149907](https://pubmed.ncbi.nlm.nih.gov/42149907/). *PLoS Negl Trop Dis*. [Epidemiology / Natural History]
Jha SK (2026). [PMID: 32491456](https://pubmed.ncbi.nlm.nih.gov/32491456/). *Unknown Journal*. [Epidemiology / Natural History]
Nair J (2026). [PMID: 42243591](https://pubmed.ncbi.nlm.nih.gov/42243591/). *Mycopathologia*. [Epidemiology / Natural History]
Xu Z (2026). [PMID: 41762036](https://pubmed.ncbi.nlm.nih.gov/41762036/). *J Dtsch Dermatol Ges*. [Case Report / Case Series]
Çalışır B (2026). [PMID: 42019460](https://pubmed.ncbi.nlm.nih.gov/42019460/). *Diagn Microbiol Infect Dis*. [Case Report / Case Series]
Demas A (2026). [PMID: 42034285](https://pubmed.ncbi.nlm.nih.gov/42034285/). *Ann Pharm Fr*. [Other]
Mishra S (2026). [PMID: 42087659](https://pubmed.ncbi.nlm.nih.gov/42087659/). *Neurol India*. [Case Report / Case Series]
Charlier P (2026). [PMID: 41076240](https://pubmed.ncbi.nlm.nih.gov/41076240/). *Ann Pharm Fr*. [Other]
Teixeira MdM (2026). [PMID: 42132385](https://pubmed.ncbi.nlm.nih.gov/42132385/). *Clin Microbiol Rev*. [Review / Meta-Analysis]